US68622P1093

ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 01:00 ET  | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…

7 hours ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025 16:30 ET  | Source: ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE…

6 months ago